Recombinant Human Hydroxycarboxylic acid receptor 3 (HCAR3)

What is HCAR3 and why is it significant for research?

HCAR3 (Hydroxycarboxylic Acid Receptor 3) is a G protein-coupled receptor encoded by the human genome that functions as a metabolite sensor. It belongs to the HCAR family, which includes HCAR1 (GPR81), HCAR2 (GPR109A), and HCAR3 (GPR109B). HCAR3 is particularly significant because it is exclusive to humans and higher primates, making it both challenging to study and potentially valuable as a therapeutic target for modulating cellular metabolism and immune responses . Unlike many other GPCRs, HCAR3 remains relatively understudied despite its therapeutic potential, positioning it as an important target for new drug discovery efforts .

How does HCAR3 differ from other HCAR family members?

Among the three HCAR family members in humans (HCAR1, HCAR2, and HCAR3), HCAR3 is unique in being exclusive to humans and higher primates . This species specificity has made it difficult to establish clear biological functions using typical animal models. While HCAR3 shares similar expression patterns with HCAR2 in immune cells and adipocytes, it has distinct ligand binding properties and potentially specialized functions . The evolutionary restriction of HCAR3 to higher primates suggests it may have evolved to serve specialized metabolic and immunological functions unique to these species .

What are the major challenges in HCAR3 research?

The primary challenges in HCAR3 research include:

• Species restriction to humans and higher primates, limiting relevant animal model availability

• Lack of experimental structures for any hydroxycarboxylic acid receptor family members, including HCAR3

• Limited knowledge about specific endogenous ligands and their physiological concentrations

• Difficulty in distinguishing HCAR3-specific functions from those of the closely related HCAR2

• Need for specialized methodologies to study receptor signaling in native cell environments

• Absence of selective pharmacological tools, particularly HCAR3 inhibitors

Where is HCAR3 predominantly expressed in human tissues?

HCAR3 is predominantly expressed in two major cell types:

• Immune cells, particularly neutrophils and macrophages

• Adipocytes (fat cells)

This expression pattern suggests a dual role in mediating metabolic and immunological responses . Unlike many GPCRs with broad expression patterns, HCAR3's restricted expression provides important clues about its physiological functions and potential as a therapeutic target. The receptor's expression in immune cells specifically points to its involvement in inflammatory processes and immune regulation, while adipocyte expression indicates roles in lipid metabolism and energy homeostasis .

How can researchers reliably detect HCAR3 expression in tissue samples?

For reliable detection of HCAR3 expression in tissue samples, researchers should employ a combination of techniques:

• RT-qPCR: Using HCAR3-specific primers to quantify mRNA expression levels, with careful primer design to distinguish from the closely related HCAR2

• Western blotting: With validated anti-HCAR3 antibodies, noting potential cross-reactivity with HCAR2

• Immunohistochemistry/Immunofluorescence: For spatial localization within tissues

• RNA sequencing: For comprehensive expression profiling

• Single-cell RNA sequencing: To determine cell-type specific expression patterns

To address potential issues with antibody specificity, validation using recombinant HCAR3 proteins as positive controls is essential . Additionally, genetic approaches using CRISPR-based gene tagging can provide higher specificity when antibody-based approaches are unreliable.

What are the primary signaling pathways activated by HCAR3?

HCAR3 primarily signals through G i/o-type G proteins, which modulate distinct second messenger pathways in different cell types :

In adipocytes, HCAR3 signaling serves to counteract cAMP-stimulating metabolic hormone signals mediated by G s-coupled receptors like the β2-adrenergic receptor . This creates a regulatory feedback mechanism for metabolic control. The distinct signaling outcomes in different cell types highlight the context-dependent nature of HCAR3 function.

How do researchers differentiate between HCAR3-specific signaling and signaling through related receptors?

Differentiating HCAR3-specific signaling from related receptors requires several methodological approaches:

• Use of receptor-selective ligands: Employ compounds with established selectivity profiles for HCAR3 over HCAR1/HCAR2

• Genetic approaches:

  • CRISPR-mediated knockout or knockdown of HCAR3

  • Selective overexpression of HCAR3 in model systems

• Pharmacological profiling with concentration-response curves to identify receptor-specific potencies

• Chimeric receptor approach: Create chimeric receptors with components from different HCAR family members to identify domains responsible for specific signaling outcomes

• High-throughput screening platforms like DCyFIR can help determine ligand specificity by testing against multiple receptors simultaneously

When interpreting results, researchers should consider potential receptor heteromerization and cross-talk between signaling pathways.

What are the known endogenous agonists of HCAR3 and their physiological relevance?

Two primary endogenous agonists of HCAR3 have been identified, each with distinct physiological contexts:

The identification of 3-OH as an HCAR3 agonist suggests that the receptor plays a role in a negative feedback loop that counteracts excessive lipolysis during periods of fatty acid metabolism . KYNA activation of HCAR3 appears to control a separate negative feedback loop that suppresses ongoing immune responses, potentially contributing to immune tolerance or resolution of inflammation . This dual ligand specificity suggests HCAR3 may integrate metabolic and immune signaling.

How can researchers develop selective synthetic agonists and antagonists for HCAR3?

Developing selective synthetic compounds for HCAR3 requires multi-faceted approaches:

• Structure-activity relationship (SAR) studies:

  • While no experimental structures exist for HCAR3 , computational modeling can help predict binding sites

  • Systematic modification of known ligands (3-OH, KYNA) to improve selectivity

  • Fragment-based drug design to identify novel chemical scaffolds

• High-throughput screening approaches:

  • Use of platforms like DCyFIR to screen compound libraries against HCAR3 and related receptors simultaneously

  • Counter-screening against HCAR1 and HCAR2 to identify selective compounds

• Evaluation criteria for candidate compounds:

  • Selectivity (>100-fold) over HCAR1/HCAR2

  • Appropriate physicochemical properties for intended applications

  • Functional characterization across multiple signaling pathways

  • Assessment in native cell contexts (adipocytes, immune cells)

• Development of allosteric modulators:

  • Target non-orthosteric binding sites for greater selectivity

  • Design positive or negative modulators to fine-tune receptor responses

Why haven't structures been resolved for HCAR3, and what approaches could overcome these challenges?

As of current research, no experimental structures have been resolved for any hydroxycarboxylic acid receptor family members, including HCAR1-3 . This structural gap presents significant challenges for structure-based drug design. Several factors contribute to this limitation:

• Technical challenges:

  • GPCRs are notoriously difficult to crystallize due to their inherent flexibility

  • Low expression levels and instability in detergent solutions

  • Multiple conformational states complicate structural determination

• Promising approaches to overcome these limitations:

  • Cryo-electron microscopy (cryo-EM): Recent advances have enabled structure determination of GPCRs without crystallization

  • Stabilizing mutations or fusion proteins to enhance receptor stability

  • Nanobody or antibody fragments as crystallization chaperones

  • Lipid cubic phase crystallization methods specifically optimized for GPCRs

The recent breakthrough in determining HCAR2 structures through cryo-EM suggests that similar approaches might be successful for HCAR3. Computational approaches using homology modeling based on the HCAR2 structure could provide interim structural insights while experimental structures are being pursued.

How can researchers use computational modeling to predict HCAR3 structure and ligand binding?

In the absence of experimental structures, computational approaches offer valuable insights:

• Homology modeling strategies:

  • Use the recently determined HCAR2 structure as a template

  • Incorporate evolutionary sequence conservation data

  • Refine models using molecular dynamics simulations

  • Validate using mutagenesis data where available

• Ligand binding site prediction:

  • Molecular docking of known ligands (3-OH, KYNA) to identify key interactions

  • Fragment-based computational screening to explore binding pocket properties

  • Molecular dynamics simulations to capture receptor flexibility

• Structure validation approaches:

  • In silico alanine scanning to predict critical ligand binding residues

  • Comparison with experimental mutagenesis data

  • Virtual screening performance against decoy compounds

• Application to drug design:

  • Structure-based virtual screening of compound libraries

  • De novo design of compounds targeting predicted binding pockets

  • Rational design of selective compounds by targeting non-conserved residues between HCAR subtypes

What is the evidence linking HCAR3 to psychiatric disorders, particularly schizophrenia?

Recent research has established compelling links between HCAR3 and psychiatric disorders:

• Genetic evidence:

  • The SNP rs2454721 in HCAR3 is significantly associated with niacin response in psychiatric patients

  • The risk allele T of rs2454721 affects niacin responses through elevated HCAR3 gene expression

  • HCAR3 has been identified as a novel schizophrenia susceptibility gene

• Phenotypic evidence:

  • Blunted niacin response (BNR) is an established endophenotype of schizophrenia

  • HCAR3 expression alterations may underlie this blunted response

  • This suggests dysregulation of HCAR3 signaling pathways in schizophrenia

• Potential mechanisms:

  • Altered immune signaling through HCAR3 may contribute to neuroinflammatory components of psychiatric disorders

  • Dysregulated tryptophan metabolism (involving KYNA) has been implicated in schizophrenia pathophysiology

  • Abnormal HCAR3 response to endogenous metabolites may disrupt normal brain function

This evidence positions HCAR3 as a significant target for further investigation in psychiatric disorders, potentially offering new therapeutic approaches .

How might HCAR3 be involved in metabolic disorders, and what therapeutic approaches could be developed?

HCAR3's role in metabolic regulation suggests several potential involvements in metabolic disorders:

• Proposed metabolic functions and disorder associations:

  • Negative feedback regulation of lipolysis through 3-OH sensing

  • Integration of fatty acid metabolism signals with adipocyte function

  • Potential dysregulation in conditions of altered lipid metabolism (obesity, diabetes)

• Therapeutic opportunities:

  • HCAR3 agonists could suppress excessive lipolysis in dyslipidemia

  • Modulators of HCAR3 signaling might regulate adipocyte function in metabolic syndrome

  • Integration of metabolic and immune functions offers unique therapeutic potential

• Challenges in therapeutic development:

  • Need to delineate HCAR3-specific effects from HCAR2 effects

  • Potential immunomodulatory side effects of metabolically-targeted compounds

  • Species differences limiting preclinical model relevance

• Metabolic research approaches:

  • Assessment of HCAR3 expression and signaling in adipose tissue from metabolic disease patients

  • Investigation of HCAR3 polymorphisms in metabolic disorder cohorts

  • Development of humanized model systems to overcome species limitations

What are the most effective expression systems for producing functional recombinant HCAR3?

For the production of functional recombinant HCAR3, several expression systems offer distinct advantages:

For functional studies, mammalian expression systems generally provide the most physiologically relevant HCAR3 protein. The DCyFIR yeast-based system offers particular advantages for high-throughput ligand discovery, allowing CRISPR integration of GPCRs directly into the yeast genome and multiplexed screening of receptor-ligand interactions .

Essential considerations for functional expression include:

• Addition of appropriate signal sequences and tags

• Codon optimization for the expression system

• Temperature and induction optimization

• Use of stabilizing additives during purification

• Validation of function through ligand binding or signaling assays

What are the optimal assay methods for studying HCAR3 activation and signaling?

Studying HCAR3 activation and signaling requires carefully selected assay methods:

• G protein-dependent signaling assays:

  • cAMP inhibition assays (HCAR3 couples to Gi/o)

  • GTPγS binding assays to measure G protein activation

  • BRET/FRET-based G protein dissociation assays for real-time measurements

  • Calcium mobilization assays (in immune cells)

• G protein-independent signaling:

  • β-arrestin recruitment assays

  • Receptor internalization assays

  • ERK phosphorylation assays

• Physiological function assays:

  • Lipolysis inhibition in adipocytes

  • Immune cell functional assays (cytokine production, migration)

  • Gene expression profiling following receptor activation

• Advanced methodologies:

  • CRISPR-based reporter systems for endogenous signaling readouts

  • Multiplexed screening platforms like DCyFIR

  • Label-free technologies (impedance, SPR) for integrated responses

  • Phosphoproteomic analysis of signaling cascades

When designing these assays, researchers should consider potential cross-talk with other signaling pathways and validate findings across multiple assay platforms.

How can researchers address the species restriction of HCAR3 when developing translational models?

The species restriction of HCAR3 to humans and higher primates presents significant challenges for translational research . Researchers can address this limitation through several innovative approaches:

• Humanized model systems:

  • CRISPR knock-in of human HCAR3 into rodent models

  • Transgenic mice expressing human HCAR3 under tissue-specific promoters

  • Patient-derived xenografts expressing native human HCAR3

• In vitro alternatives:

  • Human primary cell cultures (adipocytes, immune cells)

  • Induced pluripotent stem cell (iPSC)-derived relevant cell types

  • Organoid models incorporating human HCAR3-expressing cells

  • Microphysiological systems ("organs-on-chips") with human cells

• Computational approaches:

  • Systems biology modeling of HCAR3 pathway integration

  • Physiologically-based pharmacokinetic (PBPK) modeling to predict human responses

  • AI/ML approaches to translate findings between species

• Non-human primate considerations:

  • Ethical evaluation of when NHP models are specifically justified

  • Careful selection of primate species expressing HCAR3 most similar to human variant

  • Minimally invasive approaches when NHP models are necessary

These approaches can help overcome the translational gap caused by HCAR3's species restriction, though each comes with methodological challenges requiring careful validation.

What are the current frontiers in HCAR3 research and promising future directions?

Current frontiers in HCAR3 research span multiple domains with several promising future directions:

• Structural biology and drug discovery:

  • Determination of HCAR3 structure using cryo-EM, building on recent success with HCAR2

  • Development of the first selective HCAR3 inhibitors, currently lacking in the field

  • Design of biased ligands that selectively activate specific signaling pathways

• Metabolite sensing and signaling:

  • Identification of additional endogenous ligands beyond 3-OH and KYNA

  • Elucidation of the integrated signaling networks connecting metabolism and immunity

  • Investigation of potential HCAR3-HCAR2 heterodimers and their functional significance

• Psychiatric disorder connections:

  • Further investigation of HCAR3 as a schizophrenia susceptibility gene

  • Development of HCAR3-targeted therapies for psychiatric disorders with BNR

  • Exploration of connections between KYNA signaling, HCAR3, and neuroinflammation

• High-throughput approaches:

  • Application of multiplexed GPCR screening technologies like DCyFIR

  • Metabolomic approaches to identify novel HCAR3 ligands

  • Development of AI-driven virtual screening specifically for HCAR3

• Immune modulation:

  • Investigation of HCAR3's role in tumor immunology and potential as a cancer therapy target

  • Exploration of HCAR3 modulation for inflammatory disorders

  • Understanding of how KYNA-HCAR3 signaling regulates immune tolerance

These frontier areas represent significant opportunities for researchers to make fundamental discoveries about HCAR3 biology and develop novel therapeutic approaches.